Aurinia Pharmaceuticals Statistics Share Statistics Aurinia Pharmaceuticals has 131.63M
shares outstanding. The number of shares has increased by -5.52%
in one year.
Shares Outstanding 131.63M Shares Change (YoY) -5.52% Shares Change (QoQ) -1.63% Owned by Institutions (%) 44.63% Shares Floating 116.31M Failed to Deliver (FTD) Shares 186 FTD / Avg. Volume 0.01%
Short Selling Information The latest short interest is 10.63M, so 7.87% of the outstanding
shares have been sold short.
Short Interest 10.63M Short % of Shares Out 7.87% Short % of Float 8.6% Short Ratio (days to cover) 4.66
Valuation Ratios The PE ratio is 223.34 and the forward
PE ratio is 14.98.
Aurinia Pharmaceuticals's PEG ratio is
-2.08.
PE Ratio 223.34 Forward PE 14.98 PS Ratio 5.46 Forward PS 4.9 PB Ratio 3.4 P/FCF Ratio 29.13 PEG Ratio -2.08
Financial Ratio History Enterprise Valuation Aurinia Pharmaceuticals has an Enterprise Value (EV) of 1.28B.
EV / Sales 5.45 EV / EBITDA 40.36 EV / EBIT 28.85 EV / FCF 29.03
Financial Position The company has a current ratio of 4.57,
with a Debt / Equity ratio of 0.21.
Current Ratio 4.57 Quick Ratio 4.17 Debt / Equity 0.21 Debt / EBITDA 2.5 Debt / FCF 1.8 Interest Coverage -0.97
Financial Efficiency Return on Equity is 1.52% and Return on Invested Capital is -0.77%.
Return on Equity 1.52% Return on Assets 1.04% Return on Invested Capital -0.77% Revenue Per Employee $1.81M Profits Per Employee $44.25K Employee Count 130 Asset Turnover 0.43 Inventory Turnover 0.72
Taxes Income Tax 1.7M Effective Tax Rate 22.77%
Stock Price Statistics The stock price has increased by 109.16% in the
last 52 weeks. The beta is 1.24, so Aurinia Pharmaceuticals's
price volatility has been higher than the market average.
Beta 1.24 52-Week Price Change 109.16% 50-Day Moving Average 8.71 200-Day Moving Average 8.32 Relative Strength Index (RSI) 75.19 Average Volume (20 Days) 1,952,719
Income Statement In the last 12 months, Aurinia Pharmaceuticals had revenue of 235.13M
and earned 5.75M
in profits. Earnings per share was 0.04.
Revenue 235.13M Gross Profit 206.88M Operating Income -4.69M Net Income 5.75M EBITDA 31.73M EBIT 12.28M Earnings Per Share (EPS) 0.04
Full Income Statement Balance Sheet The company has 83.43M in cash and 79.37M in
debt, giving a net cash position of 4.06M.
Cash & Cash Equivalents 83.43M Total Debt 79.37M Net Cash 4.06M Retained Earnings -936.57M Total Assets 502.56M Working Capital 330.7M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was 44.39M
and capital expenditures -281K, giving a free cash flow of 44.11M.
Operating Cash Flow 44.39M Capital Expenditures -281K Free Cash Flow 44.11M FCF Per Share 0.31
Full Cash Flow Statement Margins Gross margin is 87.99%, with operating and profit margins of -1.99% and 2.45%.
Gross Margin 87.99% Operating Margin -1.99% Pretax Margin 3.17% Profit Margin 2.45% EBITDA Margin 13.49% EBIT Margin -1.99% FCF Margin 18.76%
Dividends & Yields AUPH does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield 0.45% FCF Yield 3.43%
Dividend Details Analyst Forecast The average price target for AUPH is $10,
which is -12.4% lower than the current price. The consensus rating is "Buy".
Price Target $10 Price Target Difference -12.4% Analyst Consensus Buy Analyst Count 3
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number 1.55 Graham Upside -86.43%
Stock Splits The last stock split was on Nov 8, 2013. It was a
backward
split with a ratio of 1:50.
Last Split Date Nov 8, 2013 Split Type backward Split Ratio 1:50
Scores Altman Z-Score 4.63 Piotroski F-Score 7
